MOBERG DERMA SIGNS DISTRIBUTION AGREEMENT WITH PERRIGO
Moberg Derma AB, Sweden, today announced a commercial agreement with Perrigo Company that covers distribution in Israel for Moberg Derma’s novel topical nail product Emtrix™ – a treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Moberg Derma assumes supply responsibility, while the distributor will be responsible for registration and promotion in Israel.
Moberg Derma has already entered distribution agreements for the Nordic countries, Canada and seven countries in the Middle East.
Moberg Derma’s CEO Peter Wolpert stated “We are very impressed of Perrigo’s approach, momentum and their focus on being first to market with new products. We are looking forward to our collaboration and are excited about the prospects.”
Perrigo’s Business Development Director Ezra Shani stated ”We are excited of the Emtrix™ opportunity and working with Moberg Derma to make it a success in Israel. The strong clinical data and the consumer-friendly packaging contribute to a truly appealing product offering.”
About Emtrix™ and nail fungus
Emtrix™ is a prescription free, topical nail product and has the potential to become first-line treatment for common nail disorders. Safety and efficacy have been demonstrated in several clinical studies including more than 500 patients. Emtrix™ has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment. Nail fungus is the most common nail disease and afflicts approximately 10% of the general population and increasing with age. The estimated global market potential exceeds USD 1 billion. The untapped potential is significant since many patients remain untreated. It is generally recognized that there is a need for new efficacious and safe topical treatments.
Contact Moberg Derma
Peter Wolpert, President and CEO
Mobile: +46 70 - 735 71 35
E-mail: peter.wolpert@mobergderma.se
About Moberg Derma
Moberg Derma AB, Stockholm, Sweden, develops and commercializes patented medical products for the treatment of skin disorders. The company focuses on innovative products based on proven compounds. Moberg Derma outlicenses product rights to partners and distributors while maintaining certain promotion rights. The company began operations at the Karolinska Institute in 2006. The principal owners are Östersjöstiftelsen (the Baltic Sea Foundation), private investors and management. For further information, please visit: www.mobergderma.se
About Perrigo Company
Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API), and pharmaceutical and medical diagnostic products. The Company is the world’s largest manufacturer of OTC pharmaceutical products for the store brand market. The Company’s primary markets and locations of manufacturing and logistics operations are the United States, Australia, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).
Tags: